This inventor holds 10 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Novartis Ag, Irm LLC. Active years: 2015-2026.
Company Filing History:
10 out of 3,974 
1 out of 152 
Years Active: 2015-2026
Title: Norio Hamamatsu: Innovator in Biomedical Research
Introduction
Norio Hamamatsu is a distinguished inventor based in Belmont, MA (US). He has made significant contributions to the field of biomedical research, holding a total of 10 patents. His work primarily focuses on developing innovative therapeutic solutions for various medical conditions.
Latest Patents
One of his latest patents is for "Fibroblast growth factor-21-Fc fusion proteins." This invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. The patent also discloses methods for treating FGF21-associated disorders, including metabolic conditions. Another notable patent is for "Antibodies against growth differentiation factor 15 and uses thereof." This patent provides monoclonal antibodies, including human antibodies, that bind to human Growth Differentiation Factor 15 protein (GDF15), along with pharmaceutical compositions and treatment methods.
Career Highlights
Norio has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Irm LLC. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.
Collaborations
Throughout his career, Norio has collaborated with notable professionals, including Brian R. Boettcher and Shari Lynn Caplan. These collaborations have further enhanced his research and innovation efforts.
Conclusion
Norio Hamamatsu's contributions to biomedical research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments and therapies.